Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(83):973–83.

CAS  PubMed  Google Scholar 

Mantese G. Gastrointestinal stromal tumor: epidemiology, diagnosis, and treatment. Curr Opin Gastroenterol. 2019;35:555–9.

CAS  PubMed  Google Scholar 

Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.

PubMed  Google Scholar 

Foong D, Zhou J, Zarrouk A, Ho V, O’Connor MD. Understanding the biology of human interstitial cells of Cajal in gastrointestinal motility. Int J Mol Sci. 2020;21:4540.

CAS  PubMed  PubMed Central  Google Scholar 

Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C, et al. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017;13:93–107.

CAS  PubMed  Google Scholar 

Kelly CM, Gutierrez Sainz L, Chi P. The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol. 2021;14:2.

CAS  PubMed  PubMed Central  Google Scholar 

Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15:131.

CAS  PubMed  PubMed Central  Google Scholar 

Adashek JJ, Janku F, Kurzrock R. Signed in blood: circulating tumor DNA in cancer diagnosis, treatment and screening. Cancers (Basel). 2021;13:3600.

CAS  PubMed  Google Scholar 

Agashe R, Kurzrock R. Circulating tumor cells: from the laboratory to the cancer clinic. Cancers (Basel). 2020;12:2361.

CAS  PubMed  Google Scholar 

Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342–9.

CAS  PubMed  Google Scholar 

Maier J, Lange T, Kerle I, Specht K, Bruegel M, Wickenhauser C, et al. Detection of mutant free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor harboring activating mutations of CKIT or PDGFRA. Clin Cancer Res. 2013;19:4854–67.

CAS  PubMed  Google Scholar 

Calderillo-Ruíz G, Pérez-Yepez EA, García-Gámez MA, Millan-Catalan O, Díaz-Romero C, Ugalde-Silva P, et al. Genomic profiling in GIST: implications in clinical outcome and future challenges. Neoplasia. 2024;48: 100959.

PubMed  PubMed Central  Google Scholar 

Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank L, et al. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. J Clin Oncol. 2015;33:634–42.

CAS  PubMed  Google Scholar 

Jilg S, Rassner M, Maier J, Waldeck S, Kehl V, Follo M, et al. Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST). Int J Cancer. 2019;145:2292–303.

CAS  PubMed  Google Scholar 

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.

Nguyen Hoang V-A, Nguyen N, Le DN, Nguyen VS, Nguyen Thi HG, Vu HT, et al. Real-world utilization and performance of circulating tumor DNA monitoring to predict recurrence in solid tumors. JCO Oncology Advances [Internet]. 2025 [cited 2025 Jun 13];e2400084. Available from: https://ascopubs.org/doi/https://doi.org/10.1200/OA-24-00084

Bach S, Sluiter NR, Beagan JJ, Mekke JM, Ket JCF, van Grieken NCT, et al. Circulating tumor DNA analysis: clinical implications for colorectal cancer patients. A systematic review. JNCI Cancer Spectr. 2019;3:pkz042.

Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20:430–5.

CAS  PubMed  Google Scholar 

Zhao X, Hou S, Hao R, Zang Y, Song D. Prognostic significance of circulating tumor DNA detection and quantification in cervical cancer: a systematic review and meta-analysis. Front Oncol. 2025;15:1566750.

PubMed  PubMed Central  Google Scholar 

Yang R, Li T, Zhang S, Shui C, Ma H, Li C. The effect of circulating tumor DNA on the prognosis of patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis. BMC Cancer. 2024;24:1434.

CAS  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021 [cited 2025 Feb 18];372:n71. Available from: https://www.bmj.com/content/372/bmj.n71

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Systematic Reviews [Internet]. 2016 [cited 2025 Apr 7];5:210. Available from: https://doi.org/10.1186/s13643-016-0384-4

Lo CK-L, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14:45.

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.

PubMed  Google Scholar 

Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Medical Research Methodology [Internet]. [cited 2025 Feb 3];21:111. Available from: 2021. https://doi.org/10.1186/s12874-021-01308-8.

Article  Google Scholar 

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

CAS  PubMed  Google Scholar 

Chapter 10: Analysing data and undertaking meta-analyses [Internet]. [cited 2025 Jun 13]. Available from: https://training.cochrane.org/handbook/current/chapter-10

Arne G, Kristiansson E, Nerman O, Kindblom L-G, Ahlman H, Nilsson B, et al. Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis. Int J Cancer. 2011;129:1149–61.

CAS  PubMed  Google Scholar 

Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schöffski P, et al. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res. 2009;15:5869–77.

CAS  PubMed  PubMed Central  Google Scholar 

George S, von Mehren M, Fletcher JA, Sun J, Zhang S, Pritchard JR, et al. Phase II Study of Ponatinib in advanced gastrointestinal stromal tumors: efficacy, safety, and impact of liquid biopsy and other biomarkers. Clin Cancer Res. 2022;28:1268–76.

CAS  PubMed  PubMed Central  Google Scholar 

Rossi S, Gasparotto D, Miceli R, Toffolatti L, Gallina G, Scaramel E, et al. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study. Am J Surg Pathol. 2015;39:922–30.

PubMed  Google Scholar 

Shen Y-Y, Ma X-L, Wang M, Zhuang C, Ni B, Tu L, et al. Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors. Cancer Med. 2020;9:6485–96.

CAS  PubMed  PubMed Central  Google Scholar 

Andersson J, Bümming P, Meis-Kindblom JM, Sihto H, Nupponen N, Joensuu H, et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology. 2006;130:1573–81.

CAS  PubMed  Google Scholar 

Gomes AL, Gouveia A, Capelinha AF, de la Cruz D, Silva P, Reis RM, et al. Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series. J Clin Pathol. 2008;61:203–8.

CAS  PubMed  Google Scholar 

Arshad J, Roberts A, Ahmed J, Cotta J, Pico BA, Kwon D, et al. Utility of circulating tumor DNA in the management of patients with GI stromal tumor: analysis of 243 patients. JCO Precis Oncol [Internet]. 2020 [cited 2025 Apr 7];66–73. Available from: https://ascopubs.org/doi/https://doi.org/10.1200/PO.19.00253

Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813–25.

CAS  PubMed  Google Scholar 

Emile J-F, Théou N, Tabone S, Cortez A, Terrier P, Chaumette M-T, et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol. 2004;2:597–605.

PubMed  Google Scholar 

Ihle MA, Fassunke J, König K, Grünewald I, Schlaak M, Kreuzberg N, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer. 2014;14:13.

Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay J-Y, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–34.

CAS  PubMed  Google Scholar 

Demetri GD, Reichardt P, Kang Y-K, Blay J-Y, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295–302.

CAS  PubMed  Google Scholar 

Brychta N, Krahn T, von Ahsen O. Detection of KRAS mutations in circulating tumor DNA by digital PCR in Early stages of pancreatic cancer. Clin Chem. 2016;62:1482–91.>

CAS  PubMed  Google Scholar 

Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.

CAS  PubMed  Google Scholar 

Patel S, Zalcberg JR. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer. 2008;44:501–9.

CAS  PubMed